ITULAZAX Post Authorization Safety (IPAS) Study: A prospective, non-interventional study assessing the safety and tolerability of ITULAZAX in adults with tree pollen allergy in real-life practice (IPAS Study)

19/09/2019
22/02/2024
EU PAS number:
EUPAS31470
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

190910-NIS-PASS-ITULAZAX Final Protocol version 1.0

English (262.52 KB - PDF) View document
Updated protocol

20220811-NIS-PASS-ITULAZAX Final Protocol version 4.0_04102022_update sponsor address

First published: 22/02/2024
English (426.86 KB - PDF) View document
Study results
Study results

2023-06-09_NI-TT-01_Overall Study Report ITULAZAX_Synopsis_Final version

English (223.86 KB - PDF) View document
Study report
Other information